Logo image of CYTH

CYCLO THERAPEUTICS INC (CYTH) Stock Fundamental Analysis

NASDAQ:CYTH - Nasdaq - US23254X2018 - Common Stock - Currency: USD

0.7206  +0.01 (+1.39%)

After market: 0.7199 0 (-0.1%)

Fundamental Rating

2

CYTH gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 556 industry peers in the Biotechnology industry. CYTH may be in some trouble as it scores bad on both profitability and health. CYTH is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CYTH has reported negative net income.
CYTH had a negative operating cash flow in the past year.
CYTH had negative earnings in each of the past 5 years.
In the past 5 years CYTH always reported negative operating cash flow.
CYTH Yearly Net Income VS EBIT VS OCF VS FCFCYTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

CYTH has a worse Return On Assets (-472.02%) than 96.65% of its industry peers.
Industry RankSector Rank
ROA -472.02%
ROE N/A
ROIC N/A
ROA(3y)-196.91%
ROA(5y)-167.39%
ROE(3y)-876.42%
ROE(5y)-703.18%
ROIC(3y)N/A
ROIC(5y)N/A
CYTH Yearly ROA, ROE, ROICCYTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -500 -1K -1.5K -2K

1.3 Margins

CYTH's Gross Margin of 91.24% is amongst the best of the industry. CYTH outperforms 91.90% of its industry peers.
In the last couple of years the Gross Margin of CYTH has remained more or less at the same level.
CYTH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.5%
GM growth 5Y0.39%
CYTH Yearly Profit, Operating, Gross MarginsCYTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

0

2. Health

2.1 Basic Checks

CYTH does not have a ROIC to compare to the WACC, probably because it is not profitable.
CYTH has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CYTH has more shares outstanding
There is no outstanding debt for CYTH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CYTH Yearly Shares OutstandingCYTH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
CYTH Yearly Total Debt VS Total AssetsCYTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

2.2 Solvency

CYTH has an Altman-Z score of -45.56. This is a bad value and indicates that CYTH is not financially healthy and even has some risk of bankruptcy.
CYTH's Altman-Z score of -45.56 is on the low side compared to the rest of the industry. CYTH is outperformed by 93.13% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -45.56
ROIC/WACCN/A
WACC10.15%
CYTH Yearly LT Debt VS Equity VS FCFCYTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M

2.3 Liquidity

A Current Ratio of 0.17 indicates that CYTH may have some problems paying its short term obligations.
CYTH has a worse Current ratio (0.17) than 96.48% of its industry peers.
A Quick Ratio of 0.16 indicates that CYTH may have some problems paying its short term obligations.
CYTH has a worse Quick ratio (0.16) than 96.30% of its industry peers.
Industry RankSector Rank
Current Ratio 0.17
Quick Ratio 0.16
CYTH Yearly Current Assets VS Current LiabilitesCYTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

5

3. Growth

3.1 Past

CYTH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.87%, which is quite impressive.
The Revenue has decreased by -8.86% in the past year.
CYTH shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.28% yearly.
EPS 1Y (TTM)44.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.34%
Revenue 1Y (TTM)-8.86%
Revenue growth 3Y6.15%
Revenue growth 5Y1.28%
Sales Q2Q%-52.98%

3.2 Future

Based on estimates for the next years, CYTH will show a very strong growth in Earnings Per Share. The EPS will grow by 20.87% on average per year.
The Revenue is expected to grow by 106.48% on average over the next years. This is a very strong growth
EPS Next Y56.84%
EPS Next 2Y25.49%
EPS Next 3Y20.87%
EPS Next 5YN/A
Revenue Next Year-41.47%
Revenue Next 2Y-14.64%
Revenue Next 3Y106.48%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CYTH Yearly Revenue VS EstimatesCYTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M
CYTH Yearly EPS VS EstimatesCYTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CYTH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CYTH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYTH Price Earnings VS Forward Price EarningsCYTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYTH Per share dataCYTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

A more expensive valuation may be justified as CYTH's earnings are expected to grow with 20.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.49%
EPS Next 3Y20.87%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CYTH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYCLO THERAPEUTICS INC

NASDAQ:CYTH (3/25/2025, 8:00:01 PM)

After market: 0.7199 0 (-0.1%)

0.7206

+0.01 (+1.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-25 2025-03-25/amc
Earnings (Next)05-13 2025-05-13
Inst Owners11.45%
Inst Owner Change0%
Ins Owners8.13%
Ins Owner Change1.89%
Market Cap23.72M
Analysts77.78
Price Target0.97 (34.61%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-50.89%
Min EPS beat(2)-68.96%
Max EPS beat(2)-32.83%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-38.61%
Min Revenue beat(2)-54.92%
Max Revenue beat(2)-22.3%
Revenue beat(4)0
Avg Revenue beat(4)-39.05%
Min Revenue beat(4)-54.92%
Max Revenue beat(4)-22.3%
Revenue beat(8)1
Avg Revenue beat(8)-43.22%
Revenue beat(12)2
Avg Revenue beat(12)-33.37%
Revenue beat(16)3
Avg Revenue beat(16)-29.66%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 27.24
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.92
EYN/A
EPS(NY)-0.68
Fwd EYN/A
FCF(TTM)-0.68
FCFYN/A
OCF(TTM)-0.68
OCFYN/A
SpS0.03
BVpS-0.41
TBVpS-0.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -472.02%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.24%
FCFM N/A
ROA(3y)-196.91%
ROA(5y)-167.39%
ROE(3y)-876.42%
ROE(5y)-703.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.5%
GM growth 5Y0.39%
F-Score3
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.17
Quick Ratio 0.16
Altman-Z -45.56
F-Score3
WACC10.15%
ROIC/WACCN/A
Cap/Depr(3y)70.81%
Cap/Depr(5y)142.49%
Cap/Sales(3y)0.98%
Cap/Sales(5y)1.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.34%
EPS Next Y56.84%
EPS Next 2Y25.49%
EPS Next 3Y20.87%
EPS Next 5YN/A
Revenue 1Y (TTM)-8.86%
Revenue growth 3Y6.15%
Revenue growth 5Y1.28%
Sales Q2Q%-52.98%
Revenue Next Year-41.47%
Revenue Next 2Y-14.64%
Revenue Next 3Y106.48%
Revenue Next 5YN/A
EBIT growth 1Y-27.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-50.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-50.22%
OCF growth 3YN/A
OCF growth 5YN/A